Neuronetics, Inc. (NASDAQ:STIM) CEO Sells $134,453.76 in Stock

Neuronetics, Inc. (NASDAQ:STIM) CEO Keith J. Sullivan sold 40,992 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $3.28, for a total transaction of $134,453.76. Following the transaction, the chief executive officer now owns 1,283,362 shares in the company, valued at approximately $4,209,427.36. The trade was a 3.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Neuronetics Stock Performance

Shares of STIM stock opened at $4.36 on Friday. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16. The firm has a market capitalization of $132.33 million, a price-to-earnings ratio of -3.54 and a beta of 2.17. Neuronetics, Inc. has a one year low of $0.52 and a one year high of $5.07. The company has a 50 day moving average price of $2.20 and a 200 day moving average price of $1.42.

Institutional Trading of Neuronetics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Tradewinds LLC. acquired a new position in Neuronetics in the fourth quarter valued at $32,000. XTX Topco Ltd purchased a new position in shares of Neuronetics in the 4th quarter worth about $49,000. Landscape Capital Management L.L.C. acquired a new position in shares of Neuronetics in the 3rd quarter valued at about $53,000. GSA Capital Partners LLP grew its holdings in shares of Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after purchasing an additional 30,837 shares during the period. Finally, David J Yvars Group grew its holdings in shares of Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock worth $75,000 after purchasing an additional 14,825 shares during the period. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.